Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Inclusion Criteria: * Healthy military or civilian males or non-pregnant, non-lactating females * Age 18-45 * Give informed consent and understand risk and benefit of study * Understands and willing to comply with all protocol procedures and time commitment * FEMALES only: surgically sterilized or received a negative pregnancy test on day of first injection AND agrees to practice adequate birth control, if necessary, for the next 7 months after first vaccination. Exclusion Criteria: * Currently has or has had a history of significant organ/system disease * History of allergy to any vaccine * Allergy to component of vaccine such as aluminum hydroxide * Presence of significant unexplained laboratory abnormality * HIV sero-positive or any other immunosuppressive state * Positive test for HBsAg, or hepatitis C * Ongoing drug abuse/dependence * Received any live vaccine, experimental products or immunosuppressive therapy in the last 28 days or inactivated vaccine in the past 14 days, or received parenteral immunoglobulin or blood products within the past 3 months * Intention to leave study area for an extended period of time during the study * Females: positive urine pregnancy test prior to vaccination